PRKN and Alzheimer disease: The mechanistic insights revealed through structural biology offer benefit in the development of novel chemical entities that could potentially activate Parkin and alleviate the mitochondrial dysfunction caused by reduced Parkin levels in AD (Quinn et al., 2020).